Results 61 to 70 of about 26,857 (227)

Elvitegravir: A New HIV Integrase Inhibitor [PDF]

Antiviral Chemistry and Chemotherapy, 2009
Integration is a distinctive and essential process in the HIV infection cycle and thus represents an attractive antiviral drug target. Integrase inhibitors combined with other classes of drug might contribute to long-lasting suppression of HIV type-1 (HIV-1) replication for many patients.
Kazuya, Shimura, Eiichi N, Kodama
openaire   +2 more sources

Innate sensing of HIV-infected cells

, 2011
Cell-free HIV-1 virions are poor stimulators of type I interferon (IFN) production. We examined here how HIV-infected cells are recognized by plasmacytoid dendritic cells (pDCs) and by other cells.
Richard E. Randall, Randall, Richard E, Mustapha Si-Tahar, Helen K W Law, Julien Pothlichet, Plumas, Joel, Lepelley, Alice, Mammano, Fabrizio, Helen K. W. Law, Richard E Randall, Schwartz, Olivier, Albert, Matthew L, Albert, Matthew L., Louis, Stephanie, Laurence Chaperot, Chaperot, Laurence, Stéphanie Louis, Pothlichet, Julien, Olivier Schwartz, Si-Tahar, Mustapha, Sourisseau, Marion, Schilte, Clementine, Law, Helen K. W., Law, Helen K W, Marion Sourisseau, Joël Plumas, Alice Lepelley, Clémentine Schilte, Fabrizio Mammano, Matthew L Albert, Matthew L. Albert, Randall, Richard Edward   +31 more
core   +1 more source

Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV‐suppressed individuals: 48 weeks and beyond

HIV Medicine, EarlyView.
Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang, Ruby Tsz‐shan Kwong, Phillip Chan, Kwok‐wai Lam, Helen Shuk‐ying Chan, Man‐yee Chu, Wilson Lam, Tak‐chiu Wu, Wai‐shing Leung, Sai‐kwong Yung, Wan‐man Ting, Annabel Kai‐tung Choy, Joe Lok‐fung Tung, Jason Ka‐wah Fong, Daniel Kai‐yeung Yeung, Man‐po Lee   +15 more
wiley   +1 more source

HIV-1 integrase inhibitors with modifications that affect their potencies against drug resistant integrase mutants.

, 2021
Integrase strand transfer inhibitors (INSTIs) block the integration step of the retroviral lifecycle and are first-line drugs used for the treatment of HIV-1/AIDS. INSTIs have a polycyclic core with heteroatom triads, chelate the metal ions at the active
Valerie E Pye (8128395), Dario Oliveira Passos (10275591), Peter Cherepanov (369), Terrence R Jr Burke (10979217), Xue Zhi Zhao (1397659), Stephen H Hughes (9449123), Steven J Smith (9449120), Dmitry Lyumkis (9045728)   +7 more
core  

Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.

PLoS ONE, 2013
Signature HIV-1 integrase mutations associated with clinical raltegravir resistance involve 1 of 3 primary genetic pathways, Y143C/R, Q148H/K/R and N155H, the latter 2 of which confer cross-resistance to elvitegravir. In accord with clinical findings, in
Felix DeAnda, Kendra E Hightower, Robert T Nolte, Kazunari Hattori, Tomokazu Yoshinaga, Takashi Kawasuji, Mark R Underwood   +6 more
doaj   +1 more source

Docking and Molecular Dynamics Calculations of Some Previously Studied and newly Designed Ligands to Catalytic Core Domain of HIV-1 Integrase and an Investigation to Effects of Conformational Changes of Protein on Docking Results

Journal of the Turkish Chemical Society, Section A: Chemistry, 2016
Nowadays, AIDS still remains as a worldwide pandemic and continues to cause many death which arise from HIV-1 virus. For nearly 35 years, drugs that target various steps of virus life cycle have been developed.
Selami Ercan
doaj   +1 more source

INSTIs and NNRTIs Potently Inhibit HIV-1 Polypurine Tract Mutants in a Single Round Infection Assay

Viruses, 2021
Integrase strand transfer inhibitors (INSTIs) are a class of antiretroviral compounds that prevent the insertion of a DNA copy of the viral genome into the host genome by targeting the viral enzyme integrase (IN).
Steven J. Smith, Andrea Ferris, Xuezhi Zhao, Gary Pauly, Joel P. Schneider, Terrence R. Burke, Stephen H. Hughes   +6 more
doaj   +1 more source

Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta‐analysis

HIV Medicine, EarlyView.
Abstract Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non‐communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood.
Melani Ratih Mahanani, Myo Chit, Sophie Mohr, Elisenda Cama i Gibernau, Svetlana Hetjens, Volker Winkler, Hans‐Michael Steffen, Florian Neuhann   +7 more
wiley   +1 more source

HIV Integrase Inhibitors

, 2013
This chapter presents the discovery, development and evolution of integrase strand transfer inhibitors. A brief overview of the first‐generation inhibitors raltegravir and elvitegravir serves to describe their landmark advancement of the field and also outline areas for further improvement.
Brian A. Johns, Takashi Kawasuji, Emile J. Velthuisen   +2 more
openaire   +4 more sources

Retrovirus-based pseudotyped virus neutralisation assays overestimate neutralising activity in sera from participants receiving integrase inhibitors

Scientific Reports
Retroviral pseudotype-based virus neutralisation assays are widely used to estimate functional immunity, but may be unsuitable for testing human immunodeficiency virus (HIV)-infected individuals receiving integrase inhibitor treatment. We evaluated these
Mhairi J. McCormack, Patawee Asamaphan, Ellen C. Hughes, Louis Banda, Stephen Kasenda, Chris Davis, Agnieszka M. Szemiel, Amelia Crampin, Abena S. Amoah, Emma C. Thomson, Antonia Ho, Brian J. Willett   +11 more
doaj   +1 more source